Second-generation drug-eluting stents (DES) were found to be associated with better clinical outcomes than first-generation DES, 2 years after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction and comorbid prediabetes.
Treatment with NSAID concomitant with antithrombotic therapy after myocardial infarction may be associated with an increased risk for cardiovascular and bleeding events.
Patients with drug-eluting stent-related in-stent restenosis (ISR) were found to have poorer long-term outcomes than patients with bare-metal stent-related ISR.
COVID-19 ICU patients exhibited distinct phenotypic traits that suggested standard VTE prophylaxis is insufficient in this population.
Men who are obese or severely obese in young adulthood have an increased risk for venous thromboembolism (VTE) later in life.
Although etiologies and traits of early and late thrombotic microangiopathy may vary, outcomes for both patient populations are similarly unfavorable.
Although the association between thrombocytosis in iron deficiency anemia is understood, researchers studied the risk for thrombotic complications.
The treatment of patients with familial hypercholesterolemia and COVID-19 with dyslipidemia medications may prevent the occurrence of thrombotic events.
The incidence of venous thromboembolism (VTE) and major bleeding is high among patients with primary central nervous system lymphoma.
The American Heart Association outlined several considerations for the management of pregnant women with CVD or CVD-related conditions.